45
Eisai
4523.T·TSETokyo JPFounded 194111,000 employees
Large CappharmaPublicNeurologyOncology
Platform: Lecanemab
Market Cap
$18B
All Drugs
6
Clinical Trials
10
Failed / Terminated
0
FDA Approved
1
Stock Price & Catalysts (4523.T)
Loading 4523.T stock data...
Drug Pipeline (6 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Gozelucimab | 452-2899 | Phase 1/2 | 2 | Nectin-4 | MDDET | ||
| Semaosocimab | 452-457 | Phase 1 | 2 | C5 | T2D | ||
| 452-2449 | 452-2449 | Preclinical | 1 | JAK1 | SLEADHD | ||
| 452-308 | 452-308 | NDA/BLA | 2 | TNFα | AMLAtopic Derm | ||
| 452-670 | 452-670 | Approved | 2 | MALT1 | Cervical Ca | ||
| 452-5607 | 452-5607 | Preclinical | 1 | PD-1 | DMDUrothelial Ca |
SEC Filings & Financial Documents
SEC filings are not available for TSE-listed companies.
Eisai trades on TSE (JP). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (9)